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See Article, pages 667–674Two decades have passed since the discovery of hep-
atitis C virus (HCV) in 1989 [1]. Despite a massively
expanded understanding of the virus and rapidly
improving treatments, there is still no eﬀective vaccine
to prevent new HCV infections. A central question in
HCV vaccine development is whether long-lasting, sus-
tained protective immunity against HCV can be
achieved. Multiple chimpanzee and human studies have
provided valuable insights into this question. However,
depending on the interpretation of these studies, the
door to vaccine development has variably been per-
ceived as open or closed.
Approximately one-third of persons will spontane-
ously clear a primary HCV infection, while others will
have a persistent infection marked by ongoing viremia.
This outcome is determined by a partially understood
complex set of virus–host interactions. The available evi-
dence indicates that the timing, magnitude, and breadth
of adaptive immune responses are important [2–8].
CD4+ T cells responses appear to be critical to coordi-
nate eﬀective immunity, which probably explains the
higher rate of HCV persistence in HIV-infected persons
with CD4+ lymphocyte depletion.
Spontaneous recovery from HCV infection indicates
that successful immunity is possible. However, reinfec-
tion has been demonstrated in chimpanzee and human
studies. In chimpanzees, reinfection with both homolo-0168-8278/$36.00  2009 European Association for the Study of the Liver.
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[9,10]. Compared to primary infection, reinfection epi-
sodes have been associated with improved control of
viral replication, an attenuated course of infection, and
an increased likelihood of clearance [11–16]. Following
both homologous and heterologous viral rechallenge,
reductions in the duration and magnitude of viremia
when compared to the initial infection have also been
observed [14,15].
Chimpanzee studies have also provided unique
insights into the nature of successful adaptive immunity.
Rapid virological control upon reinfection is associated
with HCV-speciﬁc T cell responses [13,15,16]. When
CD4+ T cells were depleted in vivo prior to reinfection,
persistent HCV infection ensued [17]. Similarly, CD8+ T
cell depletion led to prolonged HCV viremia, which was
only controlled once CD8+ T cells reappeared in the liver
[16]. In this context, cross-genotype immunity has been
documented [14], but persistence appears more likely in
the setting of heterologous re-challenge [15]. Collectively,
these data in chimpanzees suggest that immunity against
HCV can be generated by initial infection.
In humans, HCV reinfection has also been docu-
mented in a variety of settings [18–23]. Similar to what
has been observed in chimpanzees, levels of HCV vire-
mia following reinfection are lower, generally transient,
and shorter in duration than compared to the initial
infection [24,25]. Participants followed through episodes
of primary HCV infection, spontaneous clearance and
subsequent reinfection have been described [25–27].
Aberle et al. reported two cases of reinfection following
spontaneous clearance, both of whom also cleared rein-
fection [27]. In one of these cases, a strong antiviral Th1
response to NS3-4 was maintained at high levels [27]. InPublished by Elsevier B.V. All rights reserved.
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in 11 of 22 (50%) injection drug users (IDUs) with spon-
taneous HCV clearance [25]. Subsequent clearance of
reinfection was observed in nine of 11 (83%). Both the
duration and peak HCV viremia in the setting of reinfec-
tion were decreased when compared to initial infection.
Further, among reinfected participants, an increased
breadth in HCV-speciﬁc T cell and broadened neutraliz-
ing antibody responses were observed. Data from these
human studies are consistent with chimpanzee studies
and suggest that protective HCV immunity, albeit not
sterilizing, does exist in humans.
There are also a growing number of epidemiologic
cohort studies which have sought to evaluate HCV rein-
fection rates and implications for protective immunity
[28–31]. In this issue of the Journal, van de Laar et al.
evaluated HCV reinfection and superinfection among
participants with HCV seroconversion enrolled in a
large, prospective cohort of drug users in Amsterdam,
the Netherlands followed up at six monthly intervals
during the period 1985–2005 [32]. By nature of their ini-
tial acquisition of HCV infection, the study participants
represented persons at substantial risk for subsequent
exposure to HCV. Using a standardized methodology
for the virological testing of samples collected over the
20-year period, the investigators performed a detailed
clinical and virological characterization of acute HCV
infection and viremia that was detected after the acute
phase, which they classiﬁed as superinfection when the
virus detected in the blood changed (in someone with
persistent primary infection) or as reinfection when vire-
mia ﬁrst appeared to be cleared before another new
virus was detected in the blood.
Reinfection and superinfection were frequent among
the 59 participants with HCV seroconversion, with 24
participants (39%) having multiple HCV infections dur-
ing study follow-up. Among 24 participants with spon-
taneous HCV clearance of primary infection, HCV
reinfection was subsequently observed in nine, while
viremia remained negative over long-term follow-up in
14 participants, despite ongoing drug use in 50%. Rein-
fection could be conﬁrmed in two of nine participants
with HCV reinfection and the remaining seven cases
were categorized as having probable reinfection, given
that HCV RNA could not be sequenced from samples
at either the initial (n = 6) or reinfection (n = 1) time
points, likely due to low-level viremia at the time of
sequencing. Following reinfection, viral persistence was
observed in six of nine participants (two of which were
co-infected with HIV infection). However, three of seven
participants with HCV mono-infection demonstrated
prolonged viral clearance, despite ongoing risk behav-
iors for HCV acquisition over long-term follow-up.
This important study by van de Laar and colleagues
clearly demonstrates that HCV superinfection and
HCV reinfection occur frequently among IDUs andthat, with ongoing exposure, some who initially cleared
develop persistent infection while others have prolonged
viral clearance. This heterogeneity may be partially
explained by early immune responses [2–8] and/or host
genetic factors [33]. The observation that some individ-
uals with the immunological capacity to clear initial
infection develop viral persistence following reinfection
provides further evidence that protective immunity
against HCV is incomplete. Further, they observed a
similar rate of reinfection among those with HCV clear-
ance compared to the rate of infection in those previ-
ously uninfected. As the authors state in this paper,
based on the incidence rate ratio in this study, it is
tempting to imply that HCV protective immunity does
not exist at all – that the door to HCV vaccine develop-
ment is closed. However, is that conclusion justiﬁed?
Neither HCV infection of chimpanzees or humans
confers sterilizing immunity, deﬁned as absolute protec-
tion against reinfection. However, the primary goal of
vaccination is to prevent chronic hepatitis C, which
causes cirrhosis and hepatocellular cancer. Thus, the
question is whether immunity can be achieved to protect
against viral persistence.
The human studies that have attempted to answer
this question all have limitations that explain diﬀerences
in their outcomes. Notably, most limitations underesti-
mate the degree of protective immunity. For example,
diﬀerences in subject characteristics including age, eth-
nicity, risk behaviors and HIV status, may aﬀect
observed rates of primary and reinfection clearance.
Especially crucial, the actual number of HCV exposures
is unknown and proxies such as drug use practices are
incomplete at best. While chimpanzee studies count
exposures, human studies only count incidents of vire-
mia. An implication of this limitation is that long
HCV RNA testing intervals underestimate exposure
and protective immunity because reinfection events are
overlooked, while viral persistence (by deﬁnition) is
not (Fig. 1). In a study with a relatively broad testing
interval, such as in the study by van de Laar et al, cases
of reinfection and clearance would have been missed
(Fig. 1, panel A) leading to an apparent predominance
of viral persistence (Fig. 1, panel C) and the interpreta-
tion that there was a lack of protective immunity. Fur-
ther, the outcome of reinfection (clearance vs.
persistence) is often not adequately characterized
because the person was not studied again after reinfec-
tion was ﬁrst noted, again creating overestimation of
viral persistence (and lack of protective immunity) bias.
There are also limitations in the classiﬁcation of per-
sons as ‘‘reinfected” or ‘‘superinfected”. Studies of per-
sons infected by transfusion have shown that viremia
can be cleared for months and then return without
another exposure [34]. In an IDU, this pattern would
be called reinfection. If the virus evaluated at the second
point was genetically distinct from that detected at the
Fig. 1. Impact of sampling frequency on perceptions of reinfection outcome. Hypothetical virological proﬁles in (A) a participant with initial spontaneous
HCV clearance, several HCV reinfection events with reduced duration and peak HCV viremia and subsequent spontaneous clearance of reinfection in
each instance; (B) a participant with initial spontaneous HCV clearance, several HCV reinfection events with similar duration and peak HCV viremia and
subsequent spontaneous clearance of reinfection in each instance; and (C) a participant with spontaneous HCV clearance and HCV reinfection with
persistent viremia. Solid lines indicate HCV RNA levels (light grey shading indicates persistent viremia). HCV RNA assessment time points are indicated
by vertical dotted lines. Legends indicate the hypothetical frequency of HCV RNA testing (in weeks), the number of viremic events that would be identiﬁed
with such a hypothetical HCV RNA testing frequency and the apparent outcome of infection based on the last available time point for that HCV RNA
testing frequency.
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there was reinfection. However, in careful studies of per-
sons who received more than one HCV-contaminated
blood transfusion the same pattern has been reported
(donor A virus, an extended period with no detectable
viremia, then donor B virus) [35].
So, which way is it? We believe the door to develop-
ment of an HCV vaccine that protects against chronic
infection remains open. Available data suggest that the
goal is both possible yet diﬃcult. Further studies are
required to determine just how open that door is. Ide-
ally, these studies should carefully capture primary
infection and repeat events with frequent regular sam-
pling and detailed risk assessments and detailed viro-
logic and immunologic studies.Perhaps more than any other lesson, the data from
van de Laar et al. reveal the inordinately high risk of
HCV infection among IDUs and the urgency of opening
all available doors that might more eﬀectively contribute
to prevention of infection in this setting.Acknowledgements
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